Apixaban for oral antithrombotic therapy: is a new era coming? by Yong Zhang
Zhang Molecular and Cellular Therapies 2014, 2:4
http://www.molcelltherapies.com/content/2/1/4COMMENTARY Open AccessApixaban for oral antithrombotic therapy: is a
new era coming?
Yong ZhangAbstract
Apixaban, a new oral inhibitor of activated factor Xa, may simplify antithrombotic therapy with fixed doses and no
necessity for coagulation monitoring. Apixaban is non-inferior to conventional therapy (enxoaparin, followed by
warfarin) with lower risk of major bleeding in the treatment of acute venous thromboembolism. Compared
with placebo, extended treatment with apixaban may reduce the recurrence rate in patients with venous
thromboembolism. Thromboprophylaxis therapy with apixaban in surgery (hip or knee replacement) and atrial fibrillation
has been proved to be superior to warfarin or enxoaparin. Apixaban offers a convenient and more effective alternative
choice in anticoagulant therapy.
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Warfarin, as an efficient anticoagulant drug, has been in
clinical use for about 60 years. However, many food and
drug interactions increase the risk of bleeding and this,
in combination with the need for frequent monitoring,
makes it a burdensome therapy. Enoxaparin, another
anticoagulant drug, can only be administered subcutane-
ously which is an inconvenient route. Apixaban, a new
oral inhibitor of activated factor Xa may simplify anti-
thrombotic therapy with fixed doses and no requirement
for of coagulation monitoring. There have been recent
clinical trials focusing on the efficacy and safety of
apixaban in the treatment and prophylaxis of thrombo-
embolism. Apixaban is safe and effective if it is used
appropriately.Discussion
A recent large sample trial reported the efficacy and safety
of apixaban versus conventional therapy (subcutaneous
enxoaparin, followed by warfarin) in symptomatic proximal
deep-vein thrombosis or pulmonary embolism [1]. In this
double-blind study, 5395 patients were randomized into an
apixaban (at a dose of 10 mg twice daily for 7 days,
followed by 5 mg twice daily for 6 months) group and aCorrespondence: zhang.yong@zs-hospital.sh.cn
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stated.conventional therapy (subcutaneous enoxaparin, followed
by warfarin for 6 months) group. Symptomatic recurrent
venous thromboembolism or death related to venous
thromboembolism occurred in 2.3% of patients who
received apixaban and in 2.7% who received warfarin.
Major bleeding occurred in 0.6% of patients in the apix-
aban group, compared with 1.8% of patients who received
conventional (P < 0.001 for superiority). Apixaban was
non-inferior to conventional therapy with lower risk of
major bleeding.
Another recent study indicated that extended low dose
apixaban treatment may reduce the recurrence rate in
the venous thromboembolism patients who had com-
pleted 6 to 12 months of anticoagulation therapy [2].
During the 12 month therapy period, symptomatic re-
current venous thromboembolism or death from venous
thromboembolism occurred in 73 of the 829 patients
(8.8%) who were receiving placebo, as compared with 14
of the 840 patients (1.7%) who received 2.5 mg of apixa-
ban and 14 of the 813 patients (1.7%) who received 5 mg
of apixaban (P < 0.001 for both comparisons). The rates
of major or clinically relevant non-major bleeding were
similar in the placebo group (2.8%) and 2.5 mg apixaban
group (3.2%).
Apixaban may also effectively prevent thromboembol-
ism. In two randomised double-blind trails, when com-
pared with enoxaparin 40 mg daily, apixaban 2.5 mg
twice daily administration was associated with lowerhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Clinical application of apixaban. The application of apixaban in the treatment of venous thromboembolism patients and
thromboprophylaxis in surgery and atrial fibrillation patients.
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replacement (P < 0.001 and 0.0001, respectively) without
increased bleeding [3,4]. Apixaban offers a convenient
and more effective alternative to enoxaparin of thrombo-
prophylaxis in surgery. In patients with atrial fibrillation,
apixaban at a dose of 5 mg twice daily was also superior
to warfarin in preventing stroke or systemic embolism,
it caused less bleeding and resulted in lower mortality
(P < 0.001) [5].
However,in some circumstances,apixaban was still
associated with increased bleeding risk. With acutely
ill patients, with at least one additional risk factor
for venous thromboembolism, the long-term prophy-
lactic use of apixaban, administered orally at a dose
of 2.5 mg twice daily for 30 days was not superior to
a shorter course with enoxaparin subcutaneously at a
dose of 40 mg once daily for 6 to 14 days. Apixaban
was associated with significantly more major bleeding
events than enoxaparin [6]. The addition of apixaban
orally, at a dose of 5 mg twice daily, to antiplatelet
therapy in high-risk patients after suffering acute coron-
ary syndrome increased the number of major bleeding
events without a significant reduction in recurrent ische-
mic events [7].
Conclusion
Apixaban, the oral factor Xa inhibitors offers a legitimate
alternative to warfarin and enoxaparin. This novel,
breakthrough, oral anticoagulant drug has been proven
to be effective across a broad spectrum of patients in
routine care (see Figure 1). However, apixaban is not for
everyone. More information is needed as we shift from
the era of vitamin K antagonists and enoxaparin to this
new agent. The specific indications, reversal strategies,drug interactions, extremes of patient weight, bleeding,
approaches to treatment failure, and use in combination
with other antiplatelet drugs all require further research.
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